Sas Banerjee, Endoscopy Clinical Lead, Clinical Lead for Gastroenterology and Cancer Clinical Lead at Barking, Havering and Redbridge University Hospitals NHS Trust, shared a post on LinkedIn:
“We’re thrilled to announce that our article, ‘The Crucial Role of Early Diagnosis for Patients and the Nation: Understanding the Costs of Late-Stage Cancer Diagnosis,’ has been accepted for publication in BMC Cost Effectiveness and Resource Allocation!
This research, conducted at the largest District General Hospital in East London, highlights the significant economic and patient benefits of early cancer detection. Our key findings show:
Early vs. Late Diagnosis Costs: The average Direct cost of treatment for cancers detected early (Stages 1 and 2) is less than half the cost of those diagnosed late (Stages 3 and 4), at £11.2K vs. £23.8K per pathway.
Financial and Capacity Savings: Achieving the national target of 75% early detection would save £14.7M over four years, or £3.6M annually for our cohort of nearly 5K patients, allowing us to treat an additional 1,028 patients.
Value of Life: Early detection adds over £95,000 of economic value per patient (using NICE value of £ 20k per HLE year). £122k on average societal benefit out of successful treatment of cancer – given existing detection rate of approx. 53% (this average would increase if the early detection rate increased from 53 to 75%). The overall average contribution would rise if more were detected early
Health Equity: We found a disproportionate number of late-stage diagnoses among patients from more deprived areas, underscoring the need to address health inequalities.
This is one of the first projects published under BHRUT’s new Centre for Critical Care, Surgical, and Anaesthetic Research (CARES). We firmly believe and support Cancer Research UK (CRUK) vision that ‘Health is Wealth and While Tackling Cancer Locally We Can Grow Our Economy.’ We are committed to designing strategies that promote early cancer diagnosis, not only for better patient outcomes but also for the economic well-being of the NHS .”
Aruni Ghose, Co-Founder and Chief Medical Officer at OncoFlow, shared this post, adding:
“Sas Banerjee Landmark Hot off the Press! Literally a Game Changer in UK Cancer Care.”
More posts featuring Cancer Research UK on OncoDaily.
